The Endocannabinoid System: How the Most Unknown System in Your Body Works
Share
The endocannabinoid system: how the most unknown system in your body works
You have a complete biological system whose name includes the word "cannabis". It has been present in your body since you were an embryo. It regulates pain, mood, appetite, sleep and memory. And probably no one has told you about it.
The endocannabinoid system (ECS) was discovered between 1988 and 1995 by researchers trying to understand how THC produced its effects. What they found was much larger: a neural signaling system that operates in virtually all tissues of the vertebrate body, with its own molecules, its own receptors and its own enzymes.
This article documents what science really knows about the ECS: verified facts, primary sources identified by PubMed ID, and the most common errors that circulate in the public debate about cannabis.
How the endocannabinoid system was discovered
The history of the ECS is also the history of one researcher: Raphael Mechoulam (November 5, 1930 – March 9, 2023), an Israeli chemist from the Hebrew University of Jerusalem who devoted six decades to cannabinoid research. He never won the Nobel Prize—he was nominated and received the 2020 Harvey Prize, a statistical precursor to the Nobel in more than 30% of cases—but his scientific contribution defined the field.
Correction of a widespread error
Many sources cite the characterization of the CB1 receptor as "Devane et al., 1988, PNAS". This is incorrect. The 1988 Devane et al. publication appeared in Molecular Pharmacology 34(5):605-613 (PMID 2848184). The genetic cloning of CB1 by Matsuda et al. (1990) was in Nature 346:561-564. These are two distinct milestones published in two different journals.
What components the endocannabinoid system has
The receptors: CB1, CB2 and beyond
CB1 Receptor
The most abundant G protein-coupled receptor in the mammalian brain. Expressed in prefrontal cortex (cognitive functions), amygdala (emotion), hippocampus (memory), cerebellum (coordination) and basal ganglia (movement). Also present in peripheral nerve terminals, adipose tissue, liver and pancreas. Coupled to Gi/o: inhibits adenylate cyclase and reduces neurotransmitter release.
CB2 Receptor
Primary expression in the immune system: spleen, tonsils, NK cells, monocytes, macrophages, B and T lymphocytes. Also present in liver, bone and lung. Minimal brain expression under normal conditions, but increases significantly during neuroinflammation. Its activation produces mainly anti-inflammatory and immunosuppressive effects. PMC: PMC3663904
Non-classical receptors
GPR55: coupled to Gα12/13. Involved in metabolism, inflammation and pain. CBD can act as a GPR55 antagonist—relevant in epilepsy, as GPR55 has proconvulsant activity. TRPV1: capsaicin ion channel, activated by anandamide at high concentrations. GPR18: role in acute and chronic pain.
The endocannabinoids: anandamide and 2-AG
Unlike classical neurotransmitters (dopamine, serotonin, GABA), endocannabinoids are not stored in presynaptic vesicles. They are synthesized on demand, directly in the cell membrane when the system needs them, and rapidly degraded after acting.
| Characteristic | Anandamide (AEA) | 2-AG |
|---|---|---|
| Full name | N-arachidonoylethanolamine | 2-arachidonoylglycerol |
| Brain abundance | Low (reference) | ~170× more abundant |
| CB1 affinity | Partial agonist | Full agonist (greater efficacy) |
| Synthesis enzyme | NAPE-PLD | DAGL-α and DAGL-β |
| Degradation enzyme | FAAH (fatty acid amide hydrolase) | MAGL (~85%) + ABHD6 and ABHD12 |
| Primary mediator in | Stress response, pain, mood | Synaptic plasticity (DSI/DSE) |
How it works: retrograde signaling
What makes the endocannabinoid system unique within the nervous system is its direction of signaling: it works backwards compared to most neurotransmitters.
In a normal synapse, the presynaptic neuron releases neurotransmitters that act on the postsynaptic neuron. The ECS reverses that flow:
This mechanism generates two documented synaptic plasticity phenomena: DSI (depolarization-induced suppression of inhibition: reduces GABA), and DSE (depolarization-induced suppression of excitation: reduces glutamate). Documented in hippocampus and cerebellum. Source: PubMed PMID 15100161.
In 2025, a publication in PMC (PMC11873938) presented a new model for 2-AG release: extracellular microvesicles as transport vehicle, revising the classical passive diffusion model.
What the endocannabinoid system does in your body
The ECS is functionally a homeostatic system: its job is to help the body maintain balance. Its presence in virtually all tissues explains why external cannabinoids (THC or CBD) produce effects in so many different organs.
Pain regulation
CB1 and CB2 are in peripheral nociceptive neurons (dorsal root ganglia), spinal dorsal horn and descending pain modulation pathways (periaqueductal gray). The ECS modulates both acute and chronic pain. Source: PMC8819673.
Mood and stress
The ECS participates in regulation of the hypothalamic-pituitary-adrenal (HPA) axis. Glucocorticoids activate endocannabinoid signaling for rapid negative feedback to stress. Amygdala AEA inversely correlates with corticosterone levels. Source: PMC3288468.
Appetite and metabolism
Hypothalamic CB1 regulates food intake and energy metabolism. Documented interaction with leptin and ghrelin. This function led to development (and subsequent withdrawal) of rimonabant, a CB1 antagonist for obesity, withdrawn due to serious psychiatric effects.
Memory and learning
Hippocampal CB1 involved in short-term synaptic plasticity (DSI). CB1 hippocampal activation facilitates extinction of fear-associated memories—relevant for PTSD research. Also the neurobiological basis of why THC impairs short-term memory.
Immune system
CB2 in B and T lymphocytes, monocytes, macrophages, NK cells and mast cells. Its activation produces mainly anti-inflammatory effects. The ECS acts as a modulator of the immune response, limiting excessive inflammation. Source: PMC4469415.
Sleep and development
AEA increases during sleep deprivation. The ECS is involved in sleep-wake cycles. NIDA highlights its fundamental role in embryonic and fetal brain development: neurogenesis, cell differentiation, axonal elongation and synapse formation.
Why THC activates the ECS (and what exactly happens)
THC — Delta-9-tetrahydrocannabinol
- Agonist typePartial agonist of CB1 and CB2 (not a full agonist like 2-AG)
- CB1 affinity (Ki)Range 5-80 nM depending on experimental conditions. Mean Ki ~25.1 nM at human CB1 (meta-analysis PMC2190026). The lower limit (~5 nM) indicates greater potency than commonly cited
- Psychoactive effectsMediated by CB1 activation in prefrontal cortex (cognitive alteration), amygdala (anxiety or euphoria depending on dose), hippocampus (short-term memory impairment)
- Why it lasts longer than anandamideAnandamide is rapidly degraded by FAAH. THC is NOT a FAAH substrate: metabolized by hepatic CYP450 enzymes (CYP2C9, CYP3A4), producing 11-OH-THC and THC-COOH. That’s why its action is much more prolonged
- Difference vs. endogenous anandamideAnandamide is a partial agonist with low efficacy at CB1. THC has slightly higher efficacy as a partial agonist, but its resistance to metabolic degradation primarily explains its more intense and prolonged effects
Why CBD works in a completely different way
CBD — Cannabidiol
CBD is NOT a direct agonist of CB1 or CB2 at therapeutic concentrations. Its real pharmacology is more complex and completely different from THC’s:
- Negative allosteric modulator (NAM) of CB1CBD alters CB1 receptor conformation and attenuates its signaling without activating it directly. Can reduce THC’s effects when co-administered. Source: PMC4621983
- FAAH inhibitorBy inhibiting the enzyme that degrades anandamide, CBD increases endogenous AEA levels. One of its proposed therapeutic mechanisms
- TRPV1 agonistActivates the capsaicin channel. Contributes to analgesic and anti-inflammatory effects. Source: PMC6557596
- GPR55 modulatorActs as antagonist or inverse agonist at GPR55. Relevant in epilepsy: GPR55 has proconvulsant activity. Source: PMC10894036 (2024)
- 5-HT1A agonistSerotonergic receptor. Contributes to documented anxiolytic and analgesic effects of CBD. Source: PMC7700528
- AEA reuptake inhibitorIncreases extracellular availability of anandamide by inhibiting its intracellular uptake
Why CBD doesn’t produce THC’s psychoactive effects: it acts as a NEGATIVE allosteric modulator at CB1 (doesn’t activate the pathway), has molecular targets distinct from THC’s, and can partially antagonize CB1 activation by THC. Its mechanism in epilepsy—EMA-approved as Epidyolex—operates mainly through sodium channels, TRPV1 and GPR55, not CB1.
Other cannabinoids: CBG, CBN, CBC and acid forms
Minor cannabinoids and acid forms
- CBG (Cannabigerol)Partial agonist of CB2 (Ki ~152 nM). Affinity at CB1 and CB2 is 10-100× lower than THC. Also acts at TRPV1, GPR55 and alpha-2 adrenergic receptors. Documented potential in neuroprotection, inflammation and antibacterial activity. Source: PMC6021502; PubMed 29977202
- CBN (Cannabinol)Forms by oxidation/degradation of THC (not CBD) with heat, light or time. Accumulates in aged cannabis. Partial agonist at CB1 and CB2. High affinity similar to THC but lower potency. Source: PubMed 41256665 (2025)
- CBC (Cannabichromene)Low affinity for CB1 and CB2. Acts mainly at TRPV1, GPR55 and TRPM8. Activates larger sensory neuron populations. Source: PubMed 41256665 (2025)
- THCA (tetrahydrocannabinolic acid)Acid form of THC, without psychoactivity (doesn’t bind effectively to CB1). Potent PPARγ activator with documented neuroprotective activity. Decarboxylation (heat) converts it to THC
- CBDA (cannabidiolic acid)Acid form of CBD. 5-HT1A antagonist in certain contexts; documented effects on nausea (PMC8380783). Decarboxylation converts it to CBD
The endocannabinoid deficiency syndrome: hypothesis vs. evidence
In 2004, Dr. Ethan Russo published a hypothesis that has generated continuous debate: the Clinical Endocannabinoid Deficiency Syndrome (CECD).
The hypothesis: migraine, fibromyalgia and irritable bowel syndrome share common clinical and pathophysiological patterns—hyperalgesia, central sensitization—that might be explained by an underlying ECS deficiency. Cannabinoids might block the mechanisms producing pain in these conditions.
Verified Russo publications:
- 2004 — Neuro Endocrinol Lett. 25(1-2):31-39. PMID: 15159679
- 2008 — Neuro Endocrinol Lett. 29(2):192-200. PMID: 18404144
- 2016 — Cannabis Cannabinoid Res. 1(1):154-165. PMID: 28861491
Current status of the CECD hypothesis
CECD is a hypothesis with growing correlational and mechanistic evidence—not a clinical diagnosis officially recognized by WHO, EMA, FDA or AMA. It has not been validated through randomized clinical trials specifically designed to test it. The fact that the hypothesis is scientifically interesting does not mean it has been proven. This distinction is important when informing patients with migraine, fibromyalgia or IBS.
What science is discovering in 2025-2026
- New model for 2-AG release (2025): PMC11873938 proposes 2-AG release via extracellular microvesicles, not passive diffusion. If confirmed, revises the fundamental model of endocannabinoid signaling.
- Crystal structures of CB1 bound to agonists (2025): PubMed 40866700. First crystal structures of human CB1 bound to agonists, with direct implications for rational drug design.
- ECS in autism, ADHD and Alzheimer’s (2024): Systematic review PMC11202267 on ECS changes throughout life.
- CBD and cognitive function in the elderly (2025): Mini-review PMC12426524.
- Mechanism of THC action at CB1 (2025): PMC12273586 on molecular pharmacology of partial THC agonism at CB1.
Frequently asked questions
Conclusion
The endocannabinoid system is one of the most important signaling systems in the body, discovered less than 40 years ago and still actively researched. Its main components—CB1 and CB2 receptors, the endocannabinoids anandamide and 2-AG, and the enzymes FAAH and MAGL—interact in virtually all tissues to maintain homeostasis.
Understanding the ECS helps explain why external cannabinoids produce effects in so many different bodily functions, why THC and CBD have completely different pharmacology, and why research on therapeutic cannabinoids is advancing so rapidly.
What Mechoulam began in 1964 trying to understand why cannabis produced psychoactive effects ended up revealing a fundamental biological system that existed in our bodies long before humans discovered the plant.
Verified primary sources
- Gaoni & Mechoulam (1964). THC structure. JACS 86(8):1646-1647
- Devane WA et al. (1988). CB1 characterization. Molecular Pharmacology 34:605. PMID 2848184
- Matsuda LA et al. (1990). CB1 gene cloning. Nature 346:561. PMID 2165569
- Devane WA, Mechoulam R et al. (1992). Anandamide discovery. Science 258:1946. PMID 1470919
- Munro S et al. (1993). CB2 discovery. Nature 365:61.
- Russo EB (2016). CECD. Cannabis Cannabinoid Res. PMID 28861491
- PMC (2025). 2-AG release via microvesicles. PMC11873938
- PMC (2022). ECS and pain. PMC8819673
- NIDA: nida.nih.gov
